Abstract
The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.
| Original language | French |
|---|---|
| Pages (from-to) | 336-342 |
| Number of pages | 7 |
| Journal | Semaine des Hopitaux |
| Volume | 68 |
| Issue number | 12 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES. / Rea, S.; Recchia, F.; Belli, L.; Jaffrain-Rea, L.; Frati, M. L.
In: Semaine des Hopitaux, Vol. 68, No. 12, 1992, p. 336-342.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES
AU - Rea, S.
AU - Recchia, F.
AU - Belli, L.
AU - Jaffrain-Rea, L.
AU - Frati, M. L.
PY - 1992
Y1 - 1992
N2 - The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.
AB - The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.
UR - http://www.scopus.com/inward/record.url?scp=0026579165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026579165&partnerID=8YFLogxK
M3 - Articolo
VL - 68
SP - 336
EP - 342
JO - Semaine des Hopitaux
JF - Semaine des Hopitaux
SN - 0037-1777
IS - 12
ER -